A stuby led by Dr. Ana Calpena at the NanoBioPharma group, together with researchers from Ecuador, Honduras, and Mexico, have introduced a new formulation of baritinib for the topical treatment of psoriasis. In this work, a lipid formulation was used, and the lipid-based formulation of barcitinib (BCT-OS) represents a potential improvement in the topical treatment of psoriasis, especially for patients who experience side effects from systemic treatments.
Reference: Mohammadi-Meyabadi, R., Mallandrich, M., Beirampour, N., Garrós, N., Espinoza, L.C., Sosa, L., Suñer-Carbó, J., Rodríguez-Lagunas, M.J., Garduño-Ramírez, M.L., Calpena, A.C. Lipid-based formulation of baricitinib for the topical treatment of psoriasis. Pharmaceutics 2024., 16(10)., 1287. DOI:10.3390//pharmaceutics16101287